Cystic fibrosis
Drug research and approvals for cystic fibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 153 studies of cystic fibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 79 drug trials for it since 2013, FDA has 30 approved and 93 open orphan designations naming it, and the EU has 11 authorised medicines for it.
- Recruiting worldwide: 153
- Trials authorized in Canada: 79
- FDA orphan approvals: 30
- EU medicines: 11
- The PRECISION Partners Platform (P3) StudyNCT07944183 · Not reported · Imperial College London · starts Jun 23, 2026
- The Effects of Yoga Practice on Exercise Capacity, Arterial Stiffness, Respiratory Function, Peripheral Muscle…NCT07930221 · Not applicable · Hacettepe University · starts Jul 10, 2025
- Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young…NCT07930884 · Not applicable · Northwell Health · starts Jun 23, 2025
- Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese ParticipantsNCT07915024 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts Aug 6, 2026
- Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal ImpairmentNCT07915011 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts May 26, 2026
- Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic ImpairmentNCT07913009 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts Mar 16, 2026
- Diagnostic Value of Oropharyngeal Suction and Effect of Respiratory Physiotherapy on the Detection of Microorganisms in…NCT07903792 · Not applicable · Corporacion Parc Tauli · starts Jun 1, 2026
- A Precision Medicine Approach to Assess Protein Function Loss and the Potential for CFTR Function Restoration in Cystic…NCT07889973 · Not reported · Istituto Giannina Gaslini · starts Sep 1, 2024
- PERCE-MUCO: Perceptions and Expectations of People With Cystic Fibrosis Regarding a Change in TreatmentNCT07885410 · Not reported · Fondation Ildys · starts Jul 9, 2026
Approved 12
- IvacaftorCystic fibrosis transmembrane conductance regulator positive modulator
- TezacaftorCystic fibrosis transmembrane conductance regulator positive modulator
- Tobramycin70S ribosome inhibitor
- LumacaftorCystic fibrosis transmembrane conductance regulator stabiliser
- Dornase alfaDNA hydrolytic enzyme
- Mannitol
- AzithromycinBacterial 70S ribosome inhibitor
- AztreonamBacterial penicillin-binding protein inhibitor
- LevofloxacinDNA gyrase inhibitor
- ColistimethateCell membrane inhibitor
- AcetylcysteineGlutathione precursor
- Phytonadione
Phase 3 12 of 15
- ElexacaftorCystic fibrosis transmembrane conductance regulator positive modulator
- DenufosolPurinergic receptor P2Y2 agonist
- Ataluren80S Ribosome modulator
- PancrelipaseFatty acids hydrolytic enzyme
- LiprotamaseTriglyceride hydrolytic enzyme
- BamocaftorCystic fibrosis transmembrane conductance regulator positive modulator
- SomatropinGrowth hormone receptor agonist
- Glutathione
- AmikacinBacterial 70S ribosome inhibitor
- Insulin aspartInsulin receptor agonist
- ColistinCell outer membrane inhibitor
- Insulin glargineInsulin receptor agonist
Phase 2 12 of 58
- SildenafilPhosphodiesterase 5A inhibitor
- CavosonstatAlcohol dehydrogenase class III inhibitor
- GalicaftorCystic fibrosis transmembrane conductance regulator positive modulator
- Nesolicaftor
- MiglustatCeramide glucosyltransferase inhibitor
- Nitric oxideSoluble guanylate cyclase activator
- CiprofloxacinBacterial DNA gyrase inhibitor
- LosartanType-1 angiotensin II receptor antagonist
- RifampinBacterial DNA-directed RNA polymerase inhibitor
- IdrevlorideAmiloride-sensitive sodium channel, ENaC blocker
- NavocaftorCystic fibrosis transmembrane conductance regulator positive modulator
- Doconexent
Phase 1 or earlier 12 of 39
- FDL169
- 552-02 free base
- Posenacaftor
- Dirocaftor
- ItraconazoleCytochrome P450 51 inhibitor
- Ethinyl estradiolEstrogen receptor alpha agonist
- Interferon gamma-1bInterferon gamma receptor agonist
- Phenylbutanoic acidGlutamine sequestering agent
- AmelubantLeukotriene B4 receptor 1 antagonist
- Xylitol
- Genistein
- Eluforsen
How its trials ended
1,522 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 364 whose ending is known, 45% met their primary endpoint, 10% missed it and 45% stopped early.
- Completed, result not reported77651%
- Ongoing24616%
- Met its primary endpoint16211%
- Status unknown1369%
- Stopped: other or unclear976%
- Stopped: enrollment or feasibility433%
- Missed its primary endpoint372%
- Stopped: lack of efficacy101%
- Stopped: sponsor or business decision91%
- Stopped: funding5<1%
- Stopped: safety1<1%
| Jul 3, 2026 | A phase 2, multicenter, randomized, active-controlled study to assess the safety and efficacy of ANG003 at two different dose levels in subjects with exocrine…ANG003 (lipase V325, protease, amylase) / Creon | Anagram Therapeutics, Inc. | Pending |
| Dec 19, 2025 | A multicentre, lnterventional, non-inferiority study comparing a pancreatic enzyme replacement therapy formulation to standard of care, creon®, in the…EN311 | Eneapharm | Pending |
| Mar 4, 2025 | A phase 3 study evaluating the pharmacokinetics, safety, and tolerability of VX-121 / tezacaftor/ deutivacaftor triple combination therapy in cystic fibrosis…Vanzacaftor (VX-121)-tezacaftor-deutivacaftor (VX-561) /… | Vertex Pharmaceuticals | Ongoing |
| Sep 3, 2024 | A phase 3, open-label study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects 12 months of age and…Elexacaftor-tezacaftor-ivacaftor/ Ivacaftor | Vertex Pharmaceuticals | Ongoing |
| Jul 10, 2024 | A phase 2a, randomized, placebo-controlled, double blind multiple ascending dose study in patients with cystic fibrosis carrying the 3849 +10 kb c->t mutation…SPL84 | Splisense, Ltd | Ongoing |
| Jun 23, 2023 | A phase 1/2 dose-escalation study evaluating the safety, tolerability, and efficacy of VX-522 in subjects 18 years of age and older with cystic fibrosis and a…VX-522 / Ivacaftor / Zenhale / Advair / Salbutamol / Bricanyl turbuhaler | Vertex Pharmaceuticals | Ongoing |
| Apr 21, 2023 | A phase 3, open-label study evaluating the pharmacokinetics, safety, and tolerability of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects 12 to…Elexacaftor-tezacaftor-ivacaftor / Ivacaftor | Vertex Pharmaceuticals | Closed |
| Dec 8, 2022 | A phase 3 open-label study evaluating the long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis subjects with NON-F508DEL cftr…Elexacaftor (VX-445)-tezacaftor-ivacaftor / Ivacaftor | Vertex Pharmaceuticals | Ongoing |
| Sep 28, 2022 | A phase 3, open-label study evaluating the long-term safety and efficacy of VX-121/tez/d-iva combination therapy in subjects with cystic fibrosisVanzacaftor-tezacaftor-deutivacaftor | Vertex Pharmaceuticals | Ongoing |
| May 31, 2022 | A phase 3 double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of elx/tez/iva in cystic fibrosis subjects 6 years of age and…Elexacaftor-tezacaftor- ivacaftor/ Ivacaftor | Vertex Pharmaceuticals | Ongoing |
| Mar 27, 2026 | AlyftrekTreatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have… | Vertex Pharmaceuticals Incorporated | Approved |
| Mar 27, 2026 | TrikaftaTreatment of cystic fibrosis (CF) in adult and pediatric patients aged 2 years and older who have a clinical diagnosis of CF and who have… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 20, 2024 | AlyftrekTreatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 20, 2024 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| May 3, 2023 | KalydecoTreatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to… | Vertex Pharmaceuticals, Inc. | Approved |
| Apr 26, 2023 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Sep 2, 2022 | OrkambiTreatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene | Vertex Pharmaceuticals Inc. | Approved |
| Jun 8, 2021 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 21, 2020 | TrikaftaTreatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis… | Vertex Pharmaceuticals Incorporated | Approved |
| Dec 21, 2020 | SymdekoTreatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one… | Vertex Pharmaceuticals Inc. | Approved |
| Dec 21, 2020 | KalydecoTreatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance… | Vertex Pharmaceuticals, Inc. | Approved |
| Oct 30, 2020 | Bronchitol®As add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use… | Pharmaxis Europe Limited | Approved |
| Sep 24, 2020 | KalydecoKALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene… | Vertex Pharmaceuticals, Inc. | Approved |
| Oct 21, 2019 | TrikaftaTRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation… | Vertex Pharmaceuticals Incorporated | Approved |
| Jun 21, 2019 | SymdekoSYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del… | Vertex Pharmaceuticals Inc. | Approved |
| Jun 30, 2025 | AlyftrekDeutivacaftor / tezacaftor / vanzacaftor · orphan | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Aug 21, 2020 | KaftrioIvacaftor; tezacaftor; elexacaftor · orphan | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Feb 18, 2019 | Vantobra (previously Tobramycin PARI)Tobramycin | Pari Pharma GmbH | EMA ↗ |
| Oct 31, 2018 | SymkeviTezacaftor; ivacaftor · orphan | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Nov 19, 2015 | OrkambiLumacaftor; ivacaftor | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Mar 25, 2015 | QuinsairLevofloxacin | Chiesi Farmaceutici S.p.A | EMA ↗ |
| Jul 23, 2012 | KalydecoIvacaftor | Vertex Pharmaceuticals (Ireland) Limited | EMA ↗ |
| Apr 13, 2012 | BronchitolMannitol | Pharmaxis Europe Limited | EMA ↗ |
| Feb 13, 2012 | ColobreatheColistimethate sodium | Essential Pharma Limited | EMA ↗ |
| Jul 20, 2011 | Tobi PodhalerTobramycin | Viatris Healthcare Limited | EMA ↗ |
| Sep 21, 2009 | CaystonAztreonam | Gilead Sciences Ireland UC | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA